Skip to main content

Hemodynamic Monitoring

0
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Edwards Lifesciences
2 programs
AcumenTM Hypotension Prediction Index softwareN/A1 trial
invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards LifesciencesN/A1 trial
Active Trials
NCT04972266Completed702Est. Sep 2022
NCT02950649Terminated189Est. Jun 2021
Baxter International
2 programs
StarlingN/A1 trial
StarlingN/A1 trial
Active Trials
NCT05729048Withdrawn0Est. Mar 2025
NCT04648293Completed1,207Est. Feb 2024
Baxter
BaxterCosta Rica - Cartago
1 program
StarlingN/A
Medica Corp
Medica CorpMA - Bedford
1 program
hemodynamic continuous monitoringN/A1 trial
Active Trials
NCT05445037Unknown100Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Baxter InternationalStarling
Medica Corphemodynamic continuous monitoring
Edwards LifesciencesAcumenTM Hypotension Prediction Index software
Baxter InternationalStarling
Edwards Lifesciencesinvasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences

Clinical Trials (5)

Total enrollment: 2,198 patients across 5 trials

Starling/CRRT Observational Study

Start: Jul 2023Est. completion: Mar 20250
N/AWithdrawn
NCT05445037Medica Corphemodynamic continuous monitoring

Hemodynamic and Cerebral Effects Evaluation in Anesthesia

Start: Oct 2022Est. completion: Jul 2024100 patients
N/AUnknown
NCT04972266Edwards LifesciencesAcumenTM Hypotension Prediction Index software

The EU Hyprotect Registry

Start: Sep 2021Est. completion: Sep 2022702 patients
N/ACompleted

Starling Registry Study

Start: Nov 2020Est. completion: Feb 20241,207 patients
N/ACompleted
NCT02950649Edwards Lifesciencesinvasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences

Evaluation of Clinical Impact of Non-Invasive Hemodynamic Monitoring to Optimize Perioperative Care

Start: Nov 2016Est. completion: Jun 2021189 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.